NCT01643473

Brief Summary

The purpose of this study is to to culturally tailor a technology-based individualized adherence intervention for Black and Latino patients with uncontrolled HTN or T2DM, who are non-adherent to their medications, and determine its acceptability.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at below P25 for not_applicable hypertension

Timeline
Completed

Started Apr 2013

Longer than P75 for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 16, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 18, 2012

Completed
9 months until next milestone

Study Start

First participant enrolled

April 1, 2013

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 20, 2018

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2018

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

September 26, 2019

Completed
Last Updated

September 26, 2019

Status Verified

September 1, 2019

Enrollment Period

4.9 years

First QC Date

July 16, 2012

Results QC Date

June 5, 2018

Last Update Submit

September 25, 2019

Conditions

Keywords

HypertensionLatinosMedication AdherenceBlood Pressure ControlPatient-centeredBlack

Outcome Measures

Primary Outcomes (1)

  • Feasibility of Retaining Study Participants Through the 3 Month Trial

    Feasibility is assessed as the absolute number of patients that are retained in the study once they are consented and enrolled at baseline.

    3 months

Secondary Outcomes (3)

  • Change From Baseline in Mean Systolic and Diastolic Blood Pressure at 3 Months

    baseline and 3 months

  • Change From Baseline in HbA1c at 3 Months

    baseline and 3 months

  • Change From Baseline in Self-reported Medication Adherence at 3 Months

    Baseline and 3 months

Study Arms (2)

Attention Control

ACTIVE COMPARATOR

Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes

Other: Attention Control

Tailored Adherence Intervention

EXPERIMENTAL

Tablet-based tailored adherence intervention matched to patients' most salient adherence barriers

Behavioral: Adherence Intervention

Interventions

Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.

Tailored Adherence Intervention

Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes

Attention Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Have uncontrolled hypertension defined as BP\>140/90 mmHg on at least two consecutive visits in the past year (or BP\>130/80 mmHg for those with diabetes or kidney disease) and Framingham Risk Scores (FRS) \>20% (or at least one CVD risk factor including hyperlipidemia or diabetes);
  • Have been prescribed at least one antihypertensive or oral anti-diabetic medication;
  • Self-identify as Latino or African American/Black
  • Be \> 18 years of age

You may not qualify if:

  • Refuse or are unable to provide informed consent;
  • Currently participate in another hypertension study; or 2 diabetes study
  • Have significant psychiatric comorbidity
  • Plan to discontinue care at the clinic within the next 3 months
  • Vulnerable populations including adults unable to provide informed consent, pregnant women, and prisoners will be excluded from this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Union Health Center

New York, New York, 10001, United States

Location

Related Publications (2)

  • Schoenthaler A, Leon M, Butler M, Steinhaeuser K, Wardzinski W. Development and Evaluation of a Tailored Mobile Health Intervention to Improve Medication Adherence in Black Patients With Uncontrolled Hypertension and Type 2 Diabetes: Pilot Randomized Feasibility Trial. JMIR Mhealth Uhealth. 2020 Sep 23;8(9):e17135. doi: 10.2196/17135.

  • Schoenthaler A, De La Calle F, Barrios-Barrios M, Garcia A, Pitaro M, Lum A, Rosal M. A practice-based randomized controlled trial to improve medication adherence among Latinos with hypertension: study protocol for a randomized controlled trial. Trials. 2015 Jul 2;16:290. doi: 10.1186/s13063-015-0815-x.

MeSH Terms

Conditions

HypertensionMedication Adherence

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesPatient CompliancePatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Results Point of Contact

Title
Antoinette Schoenthaler
Organization
NYU School of Medicine

Study Officials

  • Antoinette Schoenthaler, EdD

    NYU Langone Health

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 16, 2012

First Posted

July 18, 2012

Study Start

April 1, 2013

Primary Completion

February 20, 2018

Study Completion

May 1, 2018

Last Updated

September 26, 2019

Results First Posted

September 26, 2019

Record last verified: 2019-09

Locations